(Q83674660)

English

Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials

scientific article published on 20 March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21424607%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

0 references

Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21424607%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

based on heuristic

inferred from title

Khaled M Abouelkhair

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21424607%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Ezzeldin M Ibrahim

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21424607%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Osama A Al-Masri

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21424607%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Najeeb C Chaudry

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21424607%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Ghieth A Kazkaz

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21424607%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

20 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21424607%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21424607%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

189

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21424607%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21424607%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

193-198

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21424607%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

https://scigraph.springernature.com/pub.10.1007/s00408-011-9286-3

0 references

Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Issues in using progression-free survival when evaluating oncology products

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2010

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Annual review of advances in lung cancer clinical research: a report for the year 2009.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progression-free survival is a surrogate for survival in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative synthesis in systematic reviews

1 reference

https://pubmed.ncbi.nlm.nih.gov/21424607

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83674660&oldid=1752576595"